Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEND Ⅱ
NCT07381803Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fexofenadine in myocardial infarction (MI), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Jan 2025; status: recruiting.
02
Drugs
fexofenadine
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT07381803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381803.